Insulin administration was discontinued and the GCIIS used only for monitoring of blood glucose (BG), when BG had fallen below 40 mg/dl and initial clinical symptoms for hypoglycaemia were observed. In controls, the GCIIS guided IHT achieved a sufficient degree of hypoglycaemia (BG 27.6 \m=+-\2.0 mg/dl; mean \m=+-\sem) and physiological responses for GH (peak 49.4 \ m=+-\ 6.7 ng/ml), Prl (peak 1766 \m=+-\614 \g=m\U/ml), ACTH (peak 76.0 \ m=+-\8.7 pg/ml) and cortisol (peak 252 \m=+-\15 ng/ml). The total amount of insulin given was 0.115 \m=+-\ 0.012 U/kg. In the patients with pituitary tumours however, the required insulin dose varied markedly from 0.090 (pituitary insufficiency) to 0.340 U/kg (Cushing's syndrome). Minimum BG obtained was 32.5 \m=+-\1.9 mg/dl. Partial impairment of hypothalamic-pituitary function and, in particular, patients requiring exogenous cortisol supplementation during stress, could be identified. In conclusion, special advantages of the GCIIS-guided IHT are: 1) Optimal insulin dosage with standardized hypoglycaemia due to automatic adjustment to the individual insulin sensitivity.
Abstract. Insulin hypoglycaemia test (IHT) for assessment of hypothalamic-pituitary-adrenocortical (HPA) function in patients with pituitary tumours is usually performed by bolus injection of insulin, a procedure which includes the risk of overdosage and/or the need of repeated administration. This study describes that a glucose controlled insulin infusion system (GCIIS) permits to perform the IHT with standardized hypoglycaemia. Ten healthy volunteers and 10 patients with pituitary tumours were studied using the GCIIS (Biostator\s=r\) on static control (Mode 1:1, BI 35, QI 10, RI 20, FI 300).
Insulin administration was discontinued and the GCIIS used only for monitoring of blood glucose (BG) , when BG had fallen below 40 mg/dl and initial clinical symptoms for hypoglycaemia were observed. In controls, the GCIIS guided IHT achieved a sufficient degree of hypoglycaemia (BG 27 .6 \m=+-\2.0 mg/dl; mean \m=+-\sem) and physiological responses for GH (peak 49.4 \ m=+-\ 6.7 ng/ml), Prl (peak 1766 \m=+-\614 \g=m\U/ml), ACTH (peak 76.0 \ m=+-\8.7 pg/ml) and cortisol (peak 252 \m=+-\15 ng/ml). The 
Glucose controlled insulin infusion system
The details of the GCIIS used for our study ( given (U/kg body weight) is also shown. Minimum blood glucose was 32.5 ± 1.9 mg/dl. Table 2 ). Fig. 3 ), which were com¬ parable to those obtained by bolus injection. In the patients with pituitary tumours, subtle or distinct impairment of function could be detected (see Table 2 ).
In conclusion, the GCIIS-guided 
